Tests alendronate for bone death in adults with sickle cell disease
Tests alendronate, a pill, in adults with sickle cell disease and bone damage.
Key facts
- Who runs it
- University of California, Davis
- Where
- Sacramento, United StatesSee the site
- Trial code
- Registry title
- Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 9 Mar 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Alendronate Sodium
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sickle cell disease and osteonecrosis (bone damage from poor blood supply) to take alendronate tablets.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography, with osteonecrosis.
Main reasons for not taking part
- Pregnant women
- Adults unable to consent
- Prisoners
- Hospital stay for any cause within 2 weeks of study entry
- Anyone who cannot lie on a DXA scanner
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written informed consent
- Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for anyone of childbearing potential at study entry
Who cannot take part
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (for any cause) within 2 weeks of study entry
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in United States.
- UC Davis Comprehensive Cancer CenterSacramento, United StatesContact: Leyla Y Teos, PhDTaking people
About the trial
What the trial wants to find out
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
The group in the trial
- Alendronate groupTreatment being tested
Single-arm prospective cohort of 30 adult with SCD
Treatment: Alendronate Sodium
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
- Plain-language title
- Tests alendronate for bone death in adults with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06016634, who can take part
- Record updated
- 16 July 2026